Chloromycetin

Trachoma, Dacryocystitis, Bacterial diarrhoea + 15 more

Treatment

4 FDA approvals

11 Active Studies for Chloromycetin

What is Chloromycetin

Chloramphenicol

The Generic name of this drug

Treatment Summary

Chloramphenicol is an antibiotic used to treat a wide range of bacterial infections. It was first isolated from a soil-dwelling bacterium in 1947 and can now be made synthetically. Chloramphenicol works by stopping the bacteria from making proteins which allows it to stop the infection. It is usually used as a last resort when other antibiotics have failed.

Chloromycetin Otic

is the brand name

Chloromycetin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Chloromycetin Otic

Chloramphenicol

1953

6

Approved as Treatment by the FDA

Chloramphenicol, otherwise known as Chloromycetin Otic, is approved by the FDA for 4 uses including Acne and Bacterial Infections .

Acne

Used to treat Acne in combination with Allantoin

Bacterial Infections

Acne Vulgaris

Used to treat Acne in combination with Allantoin

Urinary Tract Infection (UTI)

Effectiveness

How Chloromycetin Affects Patients

Chloramphenicol is a type of antibiotic that can be produced naturally or synthetically. It is very effective in fighting a wide range of infections, but can have serious side effects, so it is usually only used to treat serious illnesses such as typhoid fever. Chloramphenicol works by stopping bacteria from growing and multiplying by binding to the bacteria's ribosome and blocking protein production.

How Chloromycetin works in the body

Chloramphenicol is able to penetrate the outer wall of bacterial cells. Once inside, it binds to a protein in the ribosome, which is responsible for making proteins. This binding stops the ribosome from making proteins, which stops the bacteria from reproducing.

When to interrupt dosage

The proposed measure of Chloromycetin is contingent upon the identified condition, including Keratitis, Bacterial diarrhoea and Communicable Diseases. The degree of dosage also depends on the method of administration as specified in the table below.

Condition

Dosage

Administration

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Postoperative

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Allergic Conjunctivitis (AC)

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Bacterial conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Trachoma

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Dacryocystitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Acne Vulgaris

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Blepharitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Urinary Tract Infection (UTI)

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis, Bacterial

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

bacterial corneal ulcers

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

swelling of the eyes

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Conjunctivitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Communicable Diseases

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Disinfection

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Keratitis

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Bacterial diarrhoea

, 1000.0 mg, 250.0 mg, 0.4 %, 0.5 %, 1.0 %, 0.2 %, 5.0 %, 100.0 mg/mL, 0.01 mg/mg, 2.5 mg/mL, 5.0 mg/mL, 2.0 mg/mL, 0.04 mg/mg, 0.5 mg/mL

Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, , Ophthalmic, Ointment, Solution - Ophthalmic, Suspension, Solution, Ointment - Ophthalmic, Suspension - Auricular (otic); Ophthalmic, Auricular (otic); Ophthalmic, Ointment - Auricular (otic); Ophthalmic, Powder, for solution, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution / drops - Ophthalmic, Auricular (otic), Solution / drops - Auricular (otic), Powder, Topical, Powder, for solution - Topical, Powder - Topical, Ointment - Ophthalmic; Topical, Injection, Injection - Intravenous, Powder, for solution - Intravenous

Warnings

Chloromycetin Contraindications

Condition

Risk Level

Notes

prophylaxis of infection in minor cuts, scrapes, or burns

Do Not Combine

Communicable Diseases

Do Not Combine

There are 20 known major drug interactions with Chloromycetin.

Common Chloromycetin Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abatacept.

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Chloramphenicol.

Abetimus

Major

The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Abetimus.

Chloromycetin Toxicity & Overdose Risk

The lowest toxic dose of this drug in mice is 1500 mg/kg, and in rats it is 2500 mg/kg. Premature infants and newborns are especially vulnerable to overdosing on this drug, and the resulting symptoms are known as the "gray syndrome". These include swelling of the abdomen, vomiting, pale blue skin, weak blood circulation, and irregular breathing, which can lead to death within a few hours.

image of a doctor in a lab doing drug, clinical research

Chloromycetin Novel Uses: Which Conditions Have a Clinical Trial Featuring Chloromycetin?

41 active clinical trials are currently being conducted to assess the potential of Chloromycetin to mitigate anterior eye segment inflammation, Inflammation Corneal and superficial ocular infections.

Condition

Clinical Trials

Trial Phases

Allergic Conjunctivitis (AC)

1 Actively Recruiting

Phase 2

Conjunctivitis

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Blepharitis

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

swelling of the eyes

0 Actively Recruiting

Bacterial diarrhoea

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Dacryocystitis

0 Actively Recruiting

Trachoma

1 Actively Recruiting

Phase 4

Conjunctivitis

0 Actively Recruiting

bacterial corneal ulcers

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Postoperative

3 Actively Recruiting

Not Applicable, Early Phase 1

Keratitis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Disinfection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Chloromycetin Reviews: What are patients saying about Chloromycetin?

4.3

Patient Review

11/23/2014

Chloromycetin for Pink Eye from Bacterial Infection

Chloromycetin was very effective in treating my pink eye. The itching stopped after a few days and it cleared up completely within a week!

4

Patient Review

1/25/2013

Chloromycetin for Pink Eye from Bacterial Infection

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about chloromycetin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of antibiotic is chloromycetin?

"The study of microorganisms. Chloramphenicol is an antibiotic that was originally found in Streptomyces venezuelae. It prevents bacterial protein synthesis by disruptiing the transfer of activated amino acids from RNA to ribosomes."

Answered by AI

What are the side effects of chloromycetin?

"The medicine may cause some serious side effects, including blood problems and eye problems. Symptoms of the blood problems include pale skin, sore throat and fever, unusual bleeding or bruising, and unusual tiredness or weakness."

Answered by AI

What is chloromycetin used for?

"It will not work for other types of eye infections.

This eye drop is for treating bacterial eye infections only. Chloramphenicol stops the growth of bacteria. Do not use this drop for any other eye infections."

Answered by AI

Clinical Trials for Chloromycetin

Image of University of North Carolina in Chapel Hill, United States.

BLTR vs B-RAP for Trichiasis

18+
All Sexes
Chapel Hill, NC

The primary objective of this randomized clinical trial is to determine whether repeat trichiasis surgery performed with Bevel-Rotate Advancement Procedure (B-RAP) improves surgical success compared to Bilamellar Tarsal Rotation (BLTR) among a group of 8-10 TT surgeons in Tanzania. The study aims to enroll 1,000 individuals with PTT. The primary outcome is repeat PTT within one year after surgery. Additionally, the study will assess eyelid contour abnormalities and how they change over a two-year period as well as patient reported outcomes. If this project is successful in improving surgical outcomes, it could change the approach to treating PTT globally. Individuals with trichiasis have a significantly reduced quality of life; correcting their trichiasis long-term has the potential to improve their quality of life and their family members' quality of life considerably.

Waitlist Available
Has No Placebo

University of North Carolina

Emily Gower, PhD

Have you considered Chloromycetin clinical trials?

We made a collection of clinical trials featuring Chloromycetin, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO

Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.

Phase 4
Recruiting

University of Missouri

Kevin M Klifto, DO, PharmD

Have you considered Chloromycetin clinical trials?

We made a collection of clinical trials featuring Chloromycetin, we think they might fit your search criteria.
Go to Trials